Docosahexaenoic acid differentially affects TNFα and IL-6 expression in LPS-stimulated RAW 264.7 murine macrophages

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 97, Issue , 2015, Pages 27-34

  Honda, Kaori L ^a   Lamon Fava, Stefania ^a   Matthan, Nirupa R ^a   Wu, Dayong ^a   Lichtenstein, Alice H ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

CREB; IL 6; Macrophages; PGE2; TLR4; TNF

Indexed keywords

CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA; 3-(4-METHYLPHENYLSULFONYL)-2-PROPENENITRILE; LIPOPOLYSACCHARIDE; MESSENGER RNA; N-(2-CYCLOHEXYLOXY-4-NITROPHENYL)METHANESULFONAMIDE; NITRILE; NITROBENZENE DERIVATIVE; PEPTIDE; SN 50; SULFONAMIDE; SULFONE; TUMOR NECROSIS FACTOR;

ANIMAL CELL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; IL 6 GENE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TNF ALPHA GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

MURINAE;

ANIMALS; BLOTTING, WESTERN; CELL LINE; DINOPROSTONE; DOCOSAHEXAENOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; NF-KAPPA B; NITRILES; NITROBENZENES; PEPTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SULFONAMIDES; SULFONES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929273817     PISSN: 09523278     EISSN: 15322823     Source Type: Journal    
DOI: 10.1016/j.plefa.2015.03.002     Document Type: Article

References (64)

1. Calder P.C. Long-chain fatty acids and inflammation. Proc. Nutr. Soc. 2012, 71:284-289.
2. Honda K.L., Lamon-Fava S., Matthan N.R., Wu D., Lichtenstein A.H. EPA and DHA exposure alters the inflammatory response but not the surface expression of toll-like receptor 4 in macrophages. Lipids 2015, 50:121-129.
3. Calder P.C., Ahluwalia N., Albers R., et al. A consideration of biomarkers to be used for evaluation of inflammation in human nutritional studies. Br. J. Nutr. 2013, 109(Suppl. 1):S1-S34.
4. Branen L., Hovgaard L., Nitulescu M., Bengtsson E., Nilsson J., Jovinge S. Inhibition of tumor necrosis factor-alpha reduces atherosclerosis in apolipoprotein E knockout mice. Arterioscler. Thromb. Vasc. Biol. 2004, 24:2137-2142.
5. Sun Y., Yin M., Zhang L., Pan J. Characterization of the cytokine expression profiles of the aorta and liver of young tumor necrosis factor alpha mutant mice. Mol. Cell. Biochem. 2012, 366:59-67.
6. Xiao N., Yin M., Zhang L., et al. Tumor necrosis factor-alpha deficiency retards early fatty-streak lesion by influencing the expression of inflammatory factors in apoE-null mice. Mol. Genet. Metab. 2009, 96:239-244.
7. McLaren J.E., Michael D.R., Ashlin T.G., Ramji D.P. Cytokines, macrophage lipid metabolism and foam cells: implications for cardiovascular disease therapy. Prog. Lipid Res. 2011, 50:331-347.
8. Hashizume M., Mihara M. Atherogenic effects of TNF-alpha and IL-6 via up-regulation of scavenger receptors. Cytokine 2012, 58:424-430.
9. Legler D.F., Bruckner M., Uetz-von Allmen E., Krause P. Prostaglandin E2 at new glance: novel insights in functional diversity offer therapeutic chances. Int. J. Biochem. Cell Biol. 2010, 42:198-201.
10. Gomez I., Foudi N., Longrois D., Norel X. The role of prostaglandin E2 in human vascular inflammation. Prostaglandins Leukot. Essent. Fat. Acids 2013, 89:55-63.
11. Medeiros A., Peres-Buzalaf C., Fortino Verdan F., Serezani C.H. Prostaglandin E2 and the suppression of phagocyte innate immune responses in different organs. Mediat. Inflamm. 2012, 2012:327568.
12. Ricciotti E., FitzGerald G.A. Prostaglandins and inflammation. Arterioscler. Thromb. Vasc. Biol. 2011, 31:986-1000.
13. Akaogi J., Yamada H., Kuroda Y., Nacionales D.C., Reeves W.H., Satoh M. Prostaglandin E2 receptors EP2 and EP4 are up-regulated in peritoneal macrophages and joints of pristane-treated mice and modulate TNF-alpha and IL-6 production. J. Leukoc Biol. 2004, 76:227-236.
14. Treffkorn L., Scheibe R., Maruyama T., Dieter P. PGE2 exerts its effect on the LPS-induced release of TNF-alpha, ET-1, IL-1alpha, IL-6 and IL-10 via the EP2 and EP4 receptor in rat liver macrophages. Prostaglandins Other Lipid Mediat. 2004, 74:113-123.
15. Vassiliou E., Jing H., Ganea D. Prostaglandin E2 inhibits TNF production in murine bone marrow-derived dendritic cells. Cell. Immunol. 2003, 223:120-132.
16. Yamane H., Sugimoto Y., Tanaka S., Ichikawa A. Prostaglandin E(2) receptors, EP2 and EP4, differentially modulate TNF-alpha and IL-6 production induced by lipopolysaccharide in mouse peritoneal neutrophils. Biochem. Biophys. Res. Commun. 2000, 278:224-228.
17. Williams J.A., Pontzer C.H., Shacter E. Regulation of macrophage interleukin-6 (IL-6) and IL-10 expression by prostaglandin E2: the role of p38 mitogen-activated protein kinase. J. Interferon Cytokine Res. 2000, 20:291-298.
18. Stafford J.B., Marnett L.J. Prostaglandin E2 inhibits tumor necrosis factor-alpha RNA through PKA type I. Biochem. Biophys. Res. Commun. 2008, 366:104-109.
19. Wall E.A., Zavzavadjian J.R., Chang M.S., et al. Suppression of LPS-induced TNF-alpha production in macrophages by cAMP is mediated by PKA-AKAP95-p105. Sci. Signal. 2009, 2:ra28.
20. Ollivier V., Parry G.C., Cobb R.R., de Prost D., Mackman N. Elevated cyclic AMP inhibits NF-kappaB-mediated transcription in human monocytic cells and endothelial cells. J. Biol. Chem. 1996, 271:20828-20835.
21. Wen A.Y., Sakamoto K.M., Miller L.S. The role of the transcription factor CREB in immune function. J. Immunol. 2010, 185:6413-6419.
22. Koga K., Takaesu G., Yoshida R., et al. Cyclic adenosine monophosphate suppresses the transcription of proinflammatory cytokines via the phosphorylated c-Fos protein. Immunity 2009, 30:372-383.
23. Gerlo S., Kooijman R., Beck I.M., Kolmus K., Spooren A., Haegeman G. Cyclic AMP: a selective modulator of NF-kappaB action. Cell. Mol. Life Sci. 2011, 68:3823-3841.
24. Parry G.C., Mackman N. Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription. J. Immunol. 1997, 159:5450-5456.
25. Delgado M., Munoz-Elias E.J., Kan Y., et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun. J. Biol. Chem. 1998, 273:31427-31436.
26. Spooren A., Kooijman R., Lintermans B., et al. Cooperation of NFkappaB and CREB to induce synergistic IL-6 expression in astrocytes. Cell. Signal. 2010, 22:871-881.
27. Fujino H., Salvi S., Regan J.W. Differential regulation of phosphorylation of the cAMP response element-binding protein after activation of EP2 and EP4 prostanoid receptors by prostaglandin E2. Mol. Pharmacol. 2005, 68:251-259.
28. Kalinski P. Regulation of immune responses by prostaglandin E2. J. Immunol. 2012, 188:21-28.
29. MacKenzie K.F., Clark K., Naqvi S., et al. PGE(2) induces macrophage IL-10 production and a regulatory-like phenotype via a protein kinase A-SIK-CRTC3 pathway. J. Immunol. 2013, 190:565-577.
30. Kim Y.J., Chung H.Y. Antioxidative and anti-inflammatory actions of docosahexaenoic acid and eicosapentaenoic acid in renal epithelial cells and macrophages. J. Med. Food 2007, 10:225-231.
31. Saw C.L., Huang Y., Kong A.N. Synergistic anti-inflammatory effects of low doses of curcumin in combination with polyunsaturated fatty acids: docosahexaenoic acid or eicosapentaenoic acid. Biochem. Pharmacol. 2010, 79:421-430.
32. Norris P.C., Dennis E.A. Omega-3 fatty acids cause dramatic changes in TLR4 and purinergic eicosanoid signaling. Proc. Natl. Acad. Sci. USA 2012, 109:8517-8522.
33. Honda K.L, Lamon-Fava S., Matthan N.R., Wu D., Lichtenstein A.H. EPA and DHA exposure alters the inflammatory response but not the surface expression of toll-like receptor 4 in macrophages. Lipids 2015, 50:121-129.
34. Avni D., Ernst O., Philosoph A., Zor T. Role of CREB in modulation of TNFalpha and IL-10 expression in LPS-stimulated RAW264.7 macrophages. Mol. Immunol. 2010, 47:1396-1403.
35. Eliopoulos A.G., Dumitru C.D., Wang C.C., Cho J., Tsichlis P.N. Induction of COX-2 by LPS in macrophages is regulated by Tpl2-dependent CREB activation signals. EMBO J. 2002, 21:4831-4840.
36. Pierce J.W., Schoenleber R., Jesmok G., et al. Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J. Biol. Chem. 1997, 272:21096-21103.
37. Wang S., Wu D., Lamon-Fava S., Matthan N.R., Honda K.L., Lichtenstein A.H. In vitro fatty acid enrichment of macrophages alters inflammatory response and net cholesterol accumulation. Br. J. Nutr. 2009, 102:497-501.
38. Mullen A., Loscher C.E., Roche H.M. Anti-inflammatory effects of EPA and DHA are dependent upon time and dose-response elements associated with LPS stimulation in THP-1-derived macrophages. J. Nutr. Biochem. 2010, 21:444-450.
39. Weldon S.M., Mullen A.C., Loscher C.E., Hurley L.A., Roche H.M. Docosahexaenoic acid induces an anti-inflammatory profile in lipopolysaccharide-stimulated human THP-1 macrophages more effectively than eicosapentaenoic acid. J. Nutr. Biochem. 2007, 18:250-258.
40. Zhao G., Etherton T.D., Martin K.R., et al. Anti-inflammatory effects of polyunsaturated fatty acids in THP-1 cells. Biochem. Biophys. Res. Commun. 2005, 336:909-917.
41. Oh D.Y., Talukdar S., Bae E.J., et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010, 142:687-698.
42. Hirschfeld M., Ma Y., Weis J.H., Vogel S.N., Weis J.J. Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2. J. Immunol. 2000, 165:618-622.
43. Lee J.Y., Plakidas A., Lee W.H., et al. Differential modulation of toll-like receptors by fatty acids: preferential inhibition by n-3 polyunsaturated fatty acids. J. Lipid. Res. 2003, 44:479-486.
44. Sijben J.W., Calder P.C. Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease. Proc. Nutr. Soc. 2007, 66:237-259.
45. Deike E., Bowden R.G., Moreillon J.J., et al. The effects of fish oil supplementation on markers of inflammation in chronic kidney disease patients. J. Ren. Nutr. 2012, 22:572-577.
46. Derosa G., Cicero A.F., Fogari E., et al. Effects of n-3 PUFAs on postprandial variation of metalloproteinases, and inflammatory and insulin resistance parameters in dyslipidemic patients: evaluation with euglycemic clamp and oral fat load. J. Clin. Lipidol. 2012, 6:553-564.
47. Ferguson J.F., Mulvey C.K., Patel P.N., et al. Omega-3 PUFA supplementation and the response to evoked endotoxemia in healthy volunteers. Mol. Nutr. Food Res. 2014, 58:601-613.
48. Hassan K.S., Hassan S.K., Hijazi E.G., Khazim K.O. Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients. Ren. Fail. 2010, 32:1031-1035.
49. Koutsos A., Jackson K.G., Lockyer S., Carvalho-Wells A., Minihane A.M., Lovegrove J.A. Greater impact of dietary fat manipulation than apolipoprotein E genotype on ex vivo cytokine production - insights from the SATgenepsilon study. Cytokine 2014, 66:156-159.
50. Renz H., Gong J.H., Schmidt A., Nain M., Gemsa D. Release of tumor necrosis factor-alpha from macrophages. Enhancement and suppression are dose-dependently regulated by prostaglandin E2 and cyclic nucleotides. J. Immunol. 1988, 141:2388-2393.
51. Martel-Pelletier J., Lajeunesse D., Reboul P., Pelletier J.P. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann. Rheum. Dis. 2003, 62:501-509.
52. Mayr B., Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat. Rev. Mol. Cell Biol. 2001, 2:599-609.
53. Pestka J.J., Smolinski A.T. Deoxynivalenol: toxicology and potential effects on humans. J. Toxicol. Environ. Health: B Crit. Rev. 2005, 8:39-69.
54. Jia Q., Zhou H.R., Shi Y., Pestka J.J. Docosahexaenoic acid consumption inhibits deoxynivalenol-induced CREB/ATF1 activation and IL-6 gene transcription in mouse macrophages. J. Nutr. 2006, 136:366-372.
55. Komatsu W., Ishihara K., Murata M., Saito H., Shinohara K. Docosahexaenoic acid suppresses nitric oxide production and inducible nitric oxide synthase expression in interferon-gamma plus lipopolysaccharide-stimulated murine macrophages by inhibiting the oxidative stress. Free Radic. Biol. Med. 2003, 34:1006-1016.
56. Lee J., Rhee M.H., Kim E., Cho J.Y. BAY 11-7082 is a broad-spectrum inhibitor with anti-inflammatory activity against multiple targets. Mediat. Inflamm. 2007, 53:111-117.
57. Aderem A., Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature 2000, 406:782-787.
58. Kawai T., Akira S. Toll-like receptor downstream signaling. Arthritis Res. Ther. 2005, 7:12-19.
59. Boothby M. Specificity of sn50 for NF-kappa B?. Nat. Immunol. 2001, 2:471-472.
60. Ramirez-Carrozzi V.R., Nazarian A.A., Li C.C., et al. Selective and antagonistic functions of SWI/SNF and Mi-2beta nucleosome remodeling complexes during an inflammatory response. Genes Dev. 2006, 20:282-296.
61. Saccani S., Pantano S., Natoli G. Two waves of nuclear factor kappaB recruitment to target promoters. J. Exp. Med. 2001, 193:1351-1359.
62. Motoyama M., Yamazaki S., Eto-Kimura A., Takeshige K., Muta T. Positive and negative regulation of nuclear factor-kappaB-mediated transcription by IkappaB-zeta, an inducible nuclear protein. J. Biol. Chem. 2005, 280:7444-7451.
63. Yamazaki S., Matsuo S., Muta T., Yamamoto M., Akira S., Takeshige K. Gene-specific requirement of a nuclear protein, IkappaB-zeta, for promoter association of inflammatory transcription regulators. J. Biol. Chem. 2008, 283:32404-32411.
64. Yamazaki S., Muta T., Takeshige K. A novel IkappaB protein, IkappaB-zeta, induced by proinflammatory stimuli, negatively regulates nuclear factor-kappaB in the nuclei. J. Biol. Chem. 2001, 276:27657-27662.